Ensuring Global Access to Life-Saving Therapies
Global Partner for Named Patient Programs, Early Access & Market Access Solutions.
The challenge is not innovation — it is access.
Patients Are Still Unable to Access Life-Saving Treatments
Five points where access breaks down
Complex and fragmented regulatory pathways.
Delays in pricing & reimbursement approvals.
Lack of structured Named Patient pathways.
Limited patient identification systems.
No unified coordination across stakeholders.
Result: Delayed treatment, patient drop-offs, unmet medical need.
Where we focus
Therapeutic Focus
Rare Diseases, Oncology.
Geographic Scope
Global markets — EU, LATAM, Asia, Middle East, Africa.
Specialized in high-need, high-complexity access environments.
A Global Named Patient & Access Platform
Named Patient Import & Supply globally.
Early Access Programs (Compassionate / Expanded Access).
Managed Access Programs.
Clinical Trial Patient Identification & Recruitment.
End-to-end access coordination.
A tri-node operating network
Switzerland — HQ
Leave No One AG
- Strategic leadership
- Global partnerships
- Compliance & governance
Bulgaria — Operations Hub
- Sourcing & procurement
- Dispatch & logistics
- Billing & financial operations
India — Coordination Office
- Patient coordination
- Physician & hospital engagement
- Market development support
Integrated model ensuring Speed, Compliance, and Scalability.
Six steps, across borders
Patient Identification
Physician Engagement
Regulatory Pathway Navigation
Drug Sourcing & Supply
Import & Delivery
Treatment Continuity Support
Seamless execution across borders.
Deploying access models tailored to market realities
Compassionate & Early Use
Pre-Approval.
- Named Patient Programs (NPP)
- Early Access / Compassionate Use Programs
Managed Entry
Bridging to Reimbursement.
- Managed Access Programs (MAP)
- Coverage with Evidence Development (CED)
Financial & Value Innovation
Post-Approval.
- Managed Entry Agreements (MEA)
- Outcome-Based Contracts (OBC)
- Patient Access Schemes (PAS)
Customized architectural solutions precisely calibrated to distinct regulatory and payer environments.
One integrator, all stakeholders
The Integrator
Actively co-creating pathways across all stakeholders to align incentives and unlock access.
Standard approach vs. Leave No One execution
| Standard Industry Approach | Leave No One Execution |
|---|---|
| Variable Standards | Switzerland-based governance & credibility |
| Outsourced & Reactive | Dedicated global supply chain via Bulgaria hub |
| Disconnected Patient Pathways | Strong on-ground coordination via India |
| Generalist Focus | Deep expertise in rare diseases & oncology |
| Advisory & Consulting Only | End-to-end execution (not just advisory) |
“We don’t just design access — we deliver it.”
Unmatched scale in rare diseases
A data-driven, globally integrated platform built entirely for execution.
29 offices covering 45 markets
We execute & deliver through our majority-owned subsidiaries directly.
United States
Boston (Cambridge), Miami
Western Europe
Munich, Mannheim, Lüneburg (Germany), Zug (Switzerland), Vienna (Austria), London, Uxbridge (UK), Bari (Italy), Madrid (Spain/Portugal), Amsterdam (Benelux), Stockholm (Nordics)
Eastern Europe
Warsaw (Poland), Ljubljana (Slovenia), Tbilisi (Georgia), Vilnius (Lithuania)
Middle East & Africa
Dubai (Emirates), Jerusalem (Israel)
China
Wuxi/Shanghai, Hainan
Asia
Chennai (India), Singapore
LATAM
Mexico City, São Paulo, Buenos Aires
Our goals for every patient
Speed
Reduce time to patient access.
Reach
Enable availability of critical therapies globally.
Empowerment
Support physicians with access pathways.
Efficacy
Improve outcomes in rare diseases & oncology.
Every patient deserves a chance — regardless of geography.
Partner with Leave No One AG
At Leave No One AG, we are redefining how patients access life-saving therapies globally.
Because no patient should be left behind.
Partner with us